NILE: Should we give everything to patients with unresectable locally advanced or metastatic urothelial cancer?

Share :
Published: 13 Jun 2019
Views: 1504
Prof Matthew Galsky - The Mount Sinai Hospital, New York, USA

Prof Matthew Galsky talks to ecancer at the 2019 American Society of Clinical Oncology (ASCO) Annual Meeting about the NILE trial.

He give a brief overview of the trial, and explains how it could define the new standard of care in this setting.

The NILE trial is a large randomised international phase III study and this trial is testing a concept that hasn’t been tested in other phase III trials yet. There’s a series of ongoing or completed phase III trials which haven’t been reported yet testing the concept should we give chemotherapy, should we give immunotherapy alone or should we give chemotherapy plus immunotherapy. There are also trials testing immunotherapy doublet regimens versus chemotherapy but the NILE trial is the first trial to ask should we give everything? Should we give patients treatment with chemotherapy and doublet immunotherapy together versus chemotherapy plus single agent immunotherapy versus chemotherapy alone? This trial in the context of the other randomised trials will define our first line standard of care in the future.